DOM-VENLAFAXINE XR CAPSULE (EXTENDED RELEASE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
28-02-2013
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
Inapatikana kutoka:
DOMINION PHARMACAL
ATC kanuni:
N06AX16
INN (Jina la Kimataifa):
VENLAFAXINE
Kipimo:
75MG
Dawa fomu:
CAPSULE (EXTENDED RELEASE)
Tungo:
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
500
Dawa ya aina:
Prescription
Eneo la matibabu:
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0131294001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2013-05-17
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
DOM-VENLAFAXINE XR
VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES
37.5 MG, 75 MG AND 150 MG VENLAFAXINE, AS VENLAFAXINE HYDROCHLORIDE
Antidepressant
DOMINION PHARMACAL
6111 Royalmount Ave, Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
February 28, 2013
Submission Control No: 116569, 151422, 162398
_ _
_Dom-VENLAFAXINE XR Product Monograph _
_Page 2 of 54 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................15
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................30
OVERDOSAGE
................................................................................................................33
ACTION AND CLINICAL PHARMACOLOGY
............................................................34
STORAGE AND STABILITY
..........................................................................................37
SPECIAL HANDLING INSTRUCTIONS
.......................................................................37
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................38
PART II: SCIENTIFIC INFORMATION
...............................................................................39
PHARMACEUTICAL INFORMATION
..........................................................................39
CLINI
Soma hati kamili
